PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review

There has been significant progress in immune checkpoint inhibitor (CPI) therapy in many solid tumor types. However, only a single failed study has been published in treating Ph(-) myeloproliferative neoplasm (MPN). To make progress in CPI studies on this disease, herein, we review and summarize the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jen-Chin, Sun, Lishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143160/
https://www.ncbi.nlm.nih.gov/pubmed/35628647
http://dx.doi.org/10.3390/ijms23105837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143160/
https://www.ncbi.nlm.nih.gov/pubmed/35628647
http://dx.doi.org/10.3390/ijms23105837

Ejemplares similares